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Abstract
ME/CFS is a chronic, complex, multisystem disease that often limits the health and function-
ing of the affected patients. Diagnosing patients with ME/CFS is a challenge, and many dif-
ferent case definitions exist and are used in clinical practice and research. Even after
diagnosis, medical treatment is very challenging. Symptom relief and coping may affect how
patients live with their disease and their quality of life. There is no consensus on which diag-
nostic criteria should be used and which treatment strategies can be recommended for
patients. The purpose of the current project was to map the landscape of the Euromene
countries in respect of national guidelines and recommendations for case definition, diagno-
sis and clinical approaches for ME/CFS patients. A 23 items questionnaire was sent out by
email to the members of Euromene. The form contained questions on existing guidelines for
case definitions, treatment/management of the disease, tests and questionnaires applied,
and the prioritization of information for data sampling in research. We obtained information
from 17 countries. Five countries reported having national guidelines for diagnosis, and five
countries reported having guidelines for clinical approaches. For diagnostic purposes, the
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Fukuda criteria were most often recommended, and also the Canadian Consensus criteria,
the International Consensus Criteria and the Oxford criteria were used. A mix of diagnostic
criteria was applied within those countries having no guidelines. Many different question-
naires and tests were used for symptom registration and diagnostic investigation. For symp-
tom relief, pain and anti-depressive medication were most often recommended. Cognitive
Behavioral Therapy and Graded Exercise treatment were often recommended as disease
management and rehabilitative/palliative strategies. The lack of consistency in recommen-
dations across European countries urges the development of regulations, guidance and
standards. The results of this study will contribute to the harmonization of diagnostic criteria
and treatment for ME/CFS in Europe.
Introduction
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic disease involv-
ing central nervous system and immune system disorders, characterised by severe fatigue
lasting for at least 6 months that is medically unexplained and not relieved by resting. This
puzzling condition is a challenge for physicians and researchers especially since it is
approached differently in different European countries making difficult the sharing of expe-
rience and the evaluation of proposed therapeutic strategies. The ‘European Network on
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome’ (Euromene) project aims to establish
a homogeneous research network to attempt to synchronise databases, develop common
standards and strategies, and initiate new research projects, in order to achieve better
understanding of the disease, harmonize diagnosis and assessment methods and contribute
to the development of effective treatments in the future. The network is structured into six
working groups (epidemiology, biomarkers, socioeconomic impact, clinical and diagnostic
criteria, short term scientific missions and dissemination).
A first task was to conduct a survey in the Euromene countries about existing gaps in ME/
CFS guidelines on diagnosis and on the treatments of ME/CFS and its efficacy, in order to
identify succesful practices and approaches. The development of uniform methods for diagno-
sis and research, as well as suggestions for treatment (pharmacological and non-pharmacologi-
cal), were the main concerns.
So far, around 20 different sets of diagnostic criteria have been developed over the last 30–
40 years for diagnosing CFS and ME. The most commonly used in recent years have been the
Fukuda criteria [1], the Canadian Consensus Criteria (CCC, [2], the International Consensus
Criteria (ICC, [3]) and the Oxford criteria [4]. Recently, a new set of diagnostic criteria—the
SEID (Systemic Exertion Intolerance Disease)—from the Institute of Medicine (IOM, [5]) was
proposed, following a huge literature review of the field. The case definitions vary according to
strictness; for example, the Oxford criteria are wider than the CCC or the ICC. Using different
criteria restricts the possibility of estimating prevalence and incidence and of comparing
research results between countries. Therefore, a consensus in diagnosis and research criteria
has the potential to create more opportunities in sharing data, and establishing strong collabo-
rating research actions across research groups and country borders.
There is an ongoing discussion about which diagnostic criteria are best and should prefera-
bly be used in the diagnosis of the illness. There is a question as to whether one should use
broad or strict criteria, and whether the same criteria should be used in clinical practice as in
research. There is also an issue as to whether the criteria applied should be consensus or
ME/CFS: European practices in diagnosis and treatment
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research based. All the criteria used until today have been developed by consensus discussions
among researchers and clinicians, and it may be a problem that research is built upon consen-
sus-based case definitions.
That different criteria are applied by various research groups creates difficulties in compari-
son of research results across study samples, but even when the same criteria are applied, they
may be interpreted and used in different ways by health care providers. This is a challenge, not
only in research, but also in clinical care, and diagnostic criteria are important also for plan-
ning and management protocols, and for health services in general. Some countries, attempted
to solve these problems by creating overarching guidelines proposing the use of criteria, as
well as more specific advice in relation to diagnosis. This discussion points to the necessity of
using standardized methods for diagnosis. Using common measurement methods may also be
required for mapping of symptoms, collecting other information or for subtyping of the
patient group.
For symptom relief, illness coping strategies and counselling of patients, there are debates
and disagreements about what should be proposed to patients. No medical cure for ME/CFS
exists at this point. However, it is possible to use both pharmacological treatments and non-
pharmacological strategies to alleviate unpleasant symptoms and improve patients’ quality of
life. Further, ME/CFS may benefit from various forms of coping and self-management strate-
gies, in managing the disease and increasing or maintaining the quality of life. There are dis-
cussions within the field about which strategies should be used and therefore, the assessment
of the various approaches and advice actually used in clinical practice around Europe is essen-
tial to be documented and incorporated in the current project.
The overall aim was to obtain a better basis for research collaborations, and to develop an
overall European policy for harmonization of criteria and other strategies and managements
offered the patients. For the current project the purpose was to map the landscape of the Euro-
mene countries on national guidelines, and to make specific recommendations for criteria,
diagnosis, assessments and clinical approaches for ME/CFS patients.
Methods
This work was conducted by the ‘Clinical Resaerch Enablers and Diagnostic Criteria’ Working
Group (WG4) of Euromene network. Euromene is a COST (European Cooperation in Science
and Technology) action group, supported by the EU Framework Programme Horizon 2020
(CA15111, http://www.euromene.eu/). The Euromene group is formed from the following
European countries: Austria, Belarus, Belgium, Bulgaria, Denmark, Finland, France, Germany,
Greece, Ireland, Italy, Latvia, Norway, Poland, Portugal, Romania, Serbia, Slovenia, Spain,
Sweden, The Netherland, United Kingdom. Members were named by the COST National
Coordinator of each involved country. Euromene network gathers physicians, biologists, epi-
demiologists, psychologists, and researchers.
https://www.cost.eu/actions/CA15111/#tabs|Name:management-committee
A questionnaire was developed by the authors in collaboration with other Euromene mem-
bers. It consisted of 22 specific questions with the possibility of supplementary comments on
each question and at the very end of the form. The form contained questions on already exist-
ing guidelines for case definitions, and on treatment/management of the disease. More specifi-
cally, types of tests and questionnaires, themes assessed, and prioritization of mappings and
assessments for research, as well as existing national bio-banks, and registry and research fund-
ing, were assessed. The questionnaire was sent to members of the Euromene in August 2016.
As a few more countries were added to the network after this date, and they also received a
copy of the questionnaire.
ME/CFS: European practices in diagnosis and treatment
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The questions were: (1) National guideline for diagnosis of ME/CFS? (2) Institution issued
them and when (year)? (3) Diagnostic criteria recommended? (4) Additional blood samples or
other tests recommended to complement the clinical investigation? (5) Who conducts the
diagnosis? (Physician, psychiatrist, physiotherapist, neurologist psychologist, etc) (6) Psycho-
social investigation, cognitive assessment, or facilitation in relation to school etc. recom-
mended? (7) Neuropsychological investigations required for diagnosing and/or monitoring?
(8) Imaging techniques required for diagnosing and/or monitoring? (9) Neuroelectrophysiolo-
gical invstigations (CNS evoked potentials EMG/NCV; autonomic function test) required?
(10) Diagnosis is usually applied? (for example: G 93.3, F 48 etc)
(11) If no guidelines: diagnostic criteria most commonly used for ME/CFS diagnosis and
who diagnose the patients usually? (12) Standardized method for assessment used (question-
naires, activity assessments or electronic tools etc)? (13) National guidelines for treatment of
ME/CFS? (14) Responsible author for guidelines? (15) Disease modifying treatment suggested?
(16) Follow-up after diagnosis? (17) Procedures for symptom management? (18) Interdisci-
plinary teams involved in treatment/symptom management? (19) Rehabilitation strategies
proposed? (20) Local/regional/national register for ME/CFS? (21) Structured biobank for ME/
CFS? (22) Specific governmental research project dedicated to ME/CFS?
In total 19 countries received the questionnaire and 16 have at this point responded; Spain,
Serbia, Denmark, Italy, Latvia, Norway, UK, Germany, Belgium, Bulgaria, Romania, France,
Greece, Netherlands, Ireland, and Finland, as well as Belarus. Each Euromene member was in
charge to answer questionnaire for his/her own country. All responses were reviewed by the
WG4 former leader (EBS) and results were summarized in tables. Moreover, specific questions
were further sent out for more detailed information from the WG4 group members and from
the respective WG leaders, on for example types of tests and questionnaires applied in the
respective countries, and on the prioritization of assessment of information in order to guide
data sampling.
Results
Guidelines for diagnosis, diagnostic criteria, psychosocial or neurological
investigation (Table 1)
Twelve of the seventeen country reported having no overall national guidelines while five of
them had (Detailed data are provided in Supplemental material). The following countries
reported having national guidelines for diagnosis and diagnostic criteria on ME/CFS: Spain,
Italy, UK, Netherlands and Norway [6,7,8,9,10]. The Fukuda criteria [1] was recommended by
the Spanish, and in the guideline from the Netherlands. The Norwegian guideline recom-
mended both the CCC [2] and the Fukuda, under the condition that the applied criteria was
reported in the medical journal. Both the ICC [3] and the Fukuda were suggested in the Italian
guideline. In UK the NICE guidelines recommend the Oxford criteria [6]), and in addition a
“diagnostic process” is recommended based on a few symptoms (with main reference to the
Oxford criteria), and exclusion of other diseases. Both Fukuda and the Canadian Consensus
Criteria are also mentioned in the Nice guidelines. In addition, one country (Belarus) reported
the International Classification of Diseases -10 (ICD-10) as a guideline but had no specific
ME/CFS guideline.
Different diagnostic criteria as well as ICD-10 diagnosis are used to diagnose ME/CFS. By
those countries having no national guidelines the most frequently used case definitions is the
Fukuda definition (n = 3) and the CCC (n = 3). Also, SEID (n = 2), Holmes (n = 1) and a mix
of ICC, CCC, Fukuda and Oxford were reported used. In one country major depression and
ME/CFS: European practices in diagnosis and treatment
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functional disease was used as diagnostic criteria. What case definition was applied varied
between countries, but most countries used either Fukuda or the CCC.
Most often, and in all the guidelines, it was reported that GP/physicians or paediatricians
made the diagnosis. However, an array of other specialists was mentioned, such as neurolo-
gists, immunologists, psychiatrists, virologists, and specialists in internal medicine, infectious
diseases, and physical medicine and rehabilitation, and in cognitive behavioural therapy.
Additional blood tests were recommended in the guidelines and also applied in some of the
countries with no guidelines for diagnosis. What type of blood tests were suggested also varied
between countries. In all the guidelines, and in three of the other countries, it was recom-
mended that psychological/psychosocial factors should also be investigated. In addition, differ-
ent neuropsychological tests, imaging techniques and neuro-electrophysiological
investigations were mentioned by 2, 4 and 4 countries, respectively. The types of tests con-
ducted varied between countries.
Other diagnosis, diagnostic criteria or standardized methods applied
(Table 2)
Even in countries not having a national guideline, patients are diagnosed by using ME/CFS
case definitions or other diagnostic systems. (Table 2). The most common classification terms
from ICD-10 applied to the diagnosis of ME/CFS patients are G93.3 (n = 9) and F48 (neuras-
thenia, n = 5). G93.4, G90.9, F45.3, or R53 also were reported.
Four of the countries (Greece, Bulgaria, Finland and Russia) report using only G93.3 from
the ICD-10 and one country (Serbia) reports not using any diagnostic term. The Fukuda set of
criteria is mentioned as the preferred case definition by two of the countries (Latvia, Belgium),
and the CCC is used in Germany. Otherwise a mix of all the case definitions and psychiatric
diagnosis such as Fukuda, Canada, ICC, SEID, Major depression, Functional Disease, Holmes
or the Oxford criteria were used. It seems that the physicians who diagnose act according to
their level of knowledge on ME/CFS and/or personal preferences as regards case definition.
Regarding standard methods and tools for mapping symptoms, seven countries reported
no standardized methods while the other countries reported a variety of questionnaires applied
for assessment of symptoms such as fatigue, sleep, physical functioning, anxiety or depression.
Table 1. Guidelines for diagnosis/diagnostic criteria (psychosocial, neurological investigations etc).
Responders n = 17
National guideline for diagnosis of ME/CFS Yes: n = 5
Case definition recommended in the guidelines Fukuda (n = 2),
Canada & Fukuda (n = 1) Fukuda and ICC
(n = 1), Oxford (n = 1)
Additional blood samples or other tests recommended to
complement the clinical investigation
Yes: n = 6
Who conducts the diagnosis (Physician, psychiatrist,
physiotherapist, neurologist psychologist, etc)?
GP/physicians: n = 7
Specialists: n = 6
Psychosocial investigation, cognitive assessment, or facilitation in
relation to school etc. recommended
Yes: n = 7
Neuropsychological investigations required for diagnosing and/or
monitoring
Yes: n = 4
Imaging techniques required for diagnosing and/or monitoring Yes: n = 5
Neuro-electrophysiological investigations (CNS evoked potentials
EMG/NCV; autonomic function test) required
Yes: n = 4
https://doi.org/10.1371/journal.pone.0225995.t001
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They also reported assessment of HR and BP, muscle power and endothelial function, as well
as Compass 31: autonomic function tests were applied.
Guidelines for treatment, symptom relief and management (Table 3)
Most of the countries do not have national guidelines for treatment of ME/CFS. The following
five countries reported to have national guidelines for clinical approaches in ME/CFS: Spain,
UK, Norway, Netherlands and Belgium. Two countries reported using treatment guides for
mental health for these patients. As disease modifying treatment the following are suggested in
the existing guidelines: painkillers (n = 3), anti-viral medication (n = 2), infection control
Table 3. Guidelines for treatment, symptom relief and management.
National guidelines for treatment of ME/
CFS
Yes: n = 5
Responsible author for guidelines National health institutions: n = 6
Research ME group: n = 1
Symptomatic treatment suggested (if
indicated)
Pain killers (n = 3), anti-depressive/anxiety medication (n = 4),
anti-viral medication (n = 2), sleep (n = 1), different kinds of
syndromes (sicca, tendinopathy, metabolic syndrome, thyroid
dysfunction) and CBT (n = 3) or GET (n = 2)
Follow-up after diagnosis Yes: n = 6 (collaboration with primary care, but only if needed)
Procedures for symptom management GET/CBT (n = 8), activity regulation/pacing/mind-body strategies
(n = 3), sick-leave, psychotherapy, self-management program (8
weekly sessions), rehabilitation institutions
Interdisciplinary teams involved in
treatment/symptom management
Yes: n = 8 (differs widely, most often neurologist and psychiatrist/
psychologist)
https://doi.org/10.1371/journal.pone.0225995.t003
Table 2. Other diagnosis, diagnostic criteria or standardized methods applied.
ICD-10 diagnostic term usually applied (for example
G 93.3, F 48 etc)
G93.3, post viral fatigue syndrome: n = 9,
F48, neurasthenia: n = 5,
G93.4, unspecified encephalopathy: n = 1,
G90.9, unspecified disorder of the autonomic nervous
system: n = 1,
F45.3, somatoform autoimmune dysfunction: n = 1,
R 53, malaise and fatigue: n = 1
No ICD-10 diagnosis used: n = 4
If no guidelines: diagnostic criteria most commonly
used for ME/CFS diagnosis
Fukuda: n = 3,
Canada: n = 3,
SEID: n = 2
Major depression: n = 1,
Functional disease: n = 1,
Holmes criteria: n = 1,
USCDCP: n = 1,
Others: Mix of ICC, Canadian, Fukuda and NICE, fatigue,
day sleepiness, sleep disorders, hormonal imbalance,
exercise intolerance
Standardized methods for assessment used
(questionnaires, activity assessments or electronic
tools etc)
Yes: n = 7
Symptom questionnaires for fatigue, sleep, physical
functioning, psychological aspects (varies widely between
countries)
HR and BP sitting and standing for 10 min., assessment of
muscle power and endothelial function within trials,
Compass31: autonomic function, Modified
cardiopulmonary exercise test for diagnosis
https://doi.org/10.1371/journal.pone.0225995.t002
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(n = 1), and medication for sleep problems (n = 1). Five countries reported having follow-up
after diagnosis and collaboration with primary care if needed.
The procedures for symptom and illness management recommended were most often
Graded Exercise Therapy (GET) and Cognitive Behavioural Therapy (CBT) (n = 8), pacing/
activity regulation/mind-body strategies (n = 4), as well as sick-leave, self-management pro-
gram (8-weekly sessions) or a four-week rehabilitation stay at an institution. In most of these
countries there are multidisciplinary teams involved in treatment/management of the disease.
Rehabilitative strategies proposed most often are CBT, GET or some activity/exercise sched-
uled strategies.
Discussion
Present work is the first study trying to map the diagnostic and treatment criteria used in
European union (COST countries) for ME/CFS. The following differences between countries
were identified: application of diagnostic criteria, exclusion processes, assessments, standard-
ized tests and questionnaires, and symptom treatment and management. National guidelines
do not exist in most of the countries while five countries have comprehensive national guide-
lines for case definitions and diagnosis as well as recommendations for use of tests, question-
naires and exclusions. The existing guidelines have been developed over the last ten years:
2007 (UK), 2011 (Italy), 2013 (Netherlands), 2014 (Spain) and 2015 (Norway), respectively.
The question of which diagnostic criteria to recommend for European countries is the most
important topic under discussion. The Fukuda criteria are most often recommended in the
respective national guidelines, but also CCC and ICC are mentioned. The IOM criteria were
discussed, and ambivalence toward using them was revealed. These criteria were developed
after an extended research literature review by the Institute of Medicine in US [5], and in fact
constitute the only case definition that has a research basis, as opposed to the other criteria
that have arisen from discussions among health providers and researchers.
For clinical practice the most important argument is that the criteria should be simple and
not time consuming. Thus, for this purpose Fukuda might be the best choice although it is
somewhat broader and may include patients with other explanations for their symptoms, than,
say the CCC or the strictest ICC from 2011. Another objection to the Fukuda criteria is that
they do not require PEM (post exertional malaise) which is now considered the cardinal symp-
tom of the disease. The issue about using broad or strict criteria is more complicated than it
seems. To apply a wider set of complementary criteria for research purposes seems to be a
good idea. The use of strict criteria such as ICC carries an implication that only patients satisfy-
ing these criteria and not CCC or Fukuda, would be part of the data sample. Comparing
patients satisfying different case definitions, or searching for subsets in the illness population,
may not be helpful. The CCC was suggested as a standard case definition for research pur-
poses. The Fukuda criteria may also be applied, for those who already use them. The newest
IOM criteria labelled SEID can be complementary in clinical practice.
Diagnostic assessment relies on clinical interview and patients’ self-reported symptoms. In
addition, an extended clinical evaluation to identify underlying, contributing, and comorbid
somatic and psychiatric conditions that require treatments is recommended. Guidelines and
standard tests for exclusions are unclear, vary or are completely absent in some countries. A
few countries have multidisciplinary teams for diagnostic assessment of this patient group. In
some countries, additional psychological/psychiatric, neurological/neuropsychological as well
as other examinations are undertaken. Further clinical examination often depends on what
kind of specialists are available in the team, at the institution or nearby. Standardized question-
naires are applied for exclusions in some countries, but there is considerable variation between
ME/CFS: European practices in diagnosis and treatment
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them. There seem to be a lack of more specific guidelines for further examinations of the
patients, and this part of the diagnostic process could be harmonized between the countries. It
was suggested to use the guideline for exclusions and comorbidity in the CCC [11].
Another important issue is which questionnaires and assessment tools are most appropriate
for symptom registrations and other additional information for research. It has been identified
a wide array of questionnaires and tools for symptom assessments applied in the different
countries. Standardized and validated questionnaires for symptom recording and for classify-
ing ME/CFS on the basis of conformity to the different case definitions which exist and are
already used in four of the countries.
The DePaul Symptom Questionnaire [12] is recommended for thorough symptom record-
ing, and for identifying patients on the basis of conformity to definitions. The DSQ is an illness
specific questionnaire and, at this point, is the only instrument able to assign patients to differ-
ent case definitions. DSQ is already translated into Norwegian, Spanish and Dutch and is used
for research on the ME/CFS patient group in these countries as well as by research teams in
the UK and the US. The SF-36 (Short-Form, MOS; [13]) is a generic health related question-
naire used for research in different illness populations included ME/CFS, for assessing mental,
physical and social functioning. Four of the items from SF-36 are also part of the DSQ scoring
system. In addition, HADS (Hospital Anxiety and Depression Scale [14]) is suggested for men-
tal health assessment and for monitoring anxiety and depression. Both DSQ, SF-36 and HAD
are well-known measurement methods, and are often used for research on ME/CFS as well as
being applied by some researchers in Euromene countries. Additionally, it is necessary to
assess other health information such as family health, extended assessments on cardinal symp-
toms such as neurocognitive aspects of sleep etc.
At this point, no medical cure exists for ME/CFS. However, it is possible to assist patients
with relief of unpleasant symptoms. Medication for pain, anxiety and depression was most
commonly mentioned for symptom relief. A few countries also mentioned antiviral medica-
tion. Cognitive Behavioral therapy (CBT) and Graded Exercise Therapy (GET) were most
often recommended as methods for symptom management. Also Pacing and activity regula-
tion were mentioned and sometimes used in combination with CBT.
Patients need advice on coping and on learning self-management strategies to prevent dete-
rioration, and for maintaining and increasing quality of life. Five of the countries have national
guidelines for the management of ME/CFS, and all of them suggest Cognitive Behavioral Ther-
apy, Graded Exercise Therapy, Pacing and mind-body strategies as useful as adjunct measures
for patients, although the evidence for their effects have been questioned. A few countries only
have rehabilitation and self-management programs for CFS/ME patients. CBT, GET or pacing
were mentioned as rehabilitative and coping management offered to patients. Both CBT and
GET are controversial, and there are disagreements and uncertainty among both patients and
health providers regarding the effect of the methods. That these approaches are used as treat-
ment and self-management strategies in ME/CFS patients may imply that even if they do not
cure, they are experienced as helpful by both health-providers and patients.
Recently a review from the Spanish group in Euromene was published that should guide
suggestions for symptom treatment and counselling and for symptom management. The
review article [15] includes the following summary: “Nutritional supplementation is recom-
mended in CFS/ME patients with biochemically proven deficiencies. CFS/ME treatment
should also be optimized by the use of individualized pacing strategies, customization of CBT
and other types of counselling and behavioral therapies so as to help relieve the symptoms.
GET should be carefully modulated by an individual pacing strategy using strict case defini-
tions to avoid the push-crash cycle. Further additional larger interventions should now incor-
porate personalized integrative medicine approaches for identifying CFS/ME patients most
ME/CFS: European practices in diagnosis and treatment
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likely to respond to each type of treatment. Researchers and the medical community also need
to develop new initiatives and additional forms of individualized treatment and management
in CFS/ME in order to achieve significant improvements in quality of life, especially in those
severely ill ME cases and bed-ridden patients”.
A set of diagnostic criteria are recommended for research and clinical practice (viz. Fukuda,
and the Canadian Consensus criteria). Guidelines for exclusions, and specific suggestions for
standardized mapping of symptoms and classification to be used, are also suggested. Several
strategies may relieve symptoms or in other ways enhance coping, self-management and qual-
ity of life, and it is best is to match the approach adopted to the individual patient‘s need and
challenges.
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